TOVX revenueQ2 2026$0
- QoQ
- -100.0%
TOVX revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), down 100.0% from the prior quarter. For the full fiscal 2011 it was $0.
Theriva Biologics Inc. (TOVX) financials
For the twelve months ended Jun 30, 2026, Theriva Biologics Inc. reported -$13.13M of net income.
- Net income, TTM
- -$13.13M
- Cash
- $11.34M
- Market cap
- $8.0M
FY2016FY2025
FY2016FY2025
TOVX revenue and earnings growth
TOVX net incomeQ2 2026-$3.22M
TOVX net income was -$3.22M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$13.06M a year earlier. For the full fiscal 2025 it was -$25.25M, compared with -$25.65M in fiscal 2024.
TOVX EPSQ2 2026-$0.07
TOVX diluted EPS was -$0.07 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$2.08.
TOVX free cash flowQ4 2025-$2.88M
TOVX free cash flow was -$2.88M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$4.69M a year earlier. For the full fiscal 2025 it was -$16.70M, compared with -$16.94M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $8.60M | $12.03M | $14.31M | $11.72M | $7.80M | $5.13M | $11.08M | $11.84M | $18.78M | $29.11M |
| Selling, general and admin | $15.45M | $7.40M | $7.12M | $9.86M | $6.47M | $5.03M | $4.58M | $5.73M | $7.47M | $10.14M |
| Operating income | -$24.05M | -$26.35M | -$21.43M | -$21.58M | -$14.27M | -$10.16M | -$15.66M | -$17.57M | -$26.25M | -$39.25M |
| Pre-tax income | -$23.74M | -$25.65M | -$19.99M | -$21.11M | -$14.27M | - | - | - | - | - |
| Income tax | - | $0 | -$1.64M | -$1.43M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$25.25M | -$25.65M | -$18.35M | -$19.68M | -$14.27M | -$10.04M | -$15.30M | -$13.37M | -$15.17M | -$27.25M |
| EPS, basic | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | -$245.00 | -$1015.00 | -$1557.50 | -$2537.50 |
| EPS, diluted | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | -$245.00 | -$1015.00 | -$1557.50 | -$2537.50 |
| Diluted shares | 12.1M | 1.3M | 644,282 | 613,093.12 | 487,500.16 | 76,045.448 | 65,752.804 | 24,929.768 | 14,213.264 | 10,776.05 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.06M | $11.71M | $23.28M | $41.88M | $67.33M | $6.23M | $15.04M | $28.92M | $17.12M | $19.05M |
| Current assets | $17.47M | $16.28M | $27.40M | $45.52M | $68.86M | $7.93M | $16.43M | $29.51M | $17.94M | $21.57M |
| Goodwill | - | $0 | $5.70M | $5.53M | $0 | - | - | - | - | - |
| Total assets | $38.24M | $35.35M | $55.22M | $71.86M | $70.36M | $8.41M | $17.23M | $30.14M | $18.84M | $22.50M |
| Current liabilities | $10.01M | $7.58M | $6.74M | $7.06M | $3.55M | $2.97M | $5.28M | $3.38M | $9.79M | $19.76M |
| Short-term debt | - | - | $63.0K | $57.0K | - | - | - | - | - | - |
| Total debt | $1.67M | $92.0K | $162.0K | $221.0K | - | - | - | - | - | - |
| Total liabilities | $22.86M | $16.29M | $15.52M | $17.30M | $4.96M | $3.15M | $5.75M | $3.69M | $10.20M | $20.25M |
| Shareholders' equity | $15.38M | $19.07M | $36.96M | $51.83M | $65.41M | -$7.54M | -$1.06M | $14.16M | -$3.41M | $2.26M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.67M | -$16.94M | -$19.00M | -$19.08M | -$12.89M | -$12.17M | -$13.87M | -$17.28M | -$20.20M | -$27.90M |
| Capital expenditures | $35.0K | $1.0K | $202.0K | $116.0K | $14.0K | $9.0K | $0 | $7.0K | $212.0K | $569.0K |
| Free cash flow | -$16.70M | -$16.94M | -$19.20M | -$19.20M | -$12.90M | -$12.18M | -$13.87M | -$17.29M | -$20.42M | -$28.47M |
| Investing cash flow | -$35.0K | -$1.0K | -$202.0K | -$4.40M | -$14.0K | -$9.0K | $0 | -$7.0K | -$212.0K | -$569.0K |
| Financing cash flow | $18.19M | $5.50M | $625.0K | -$1.93M | $74.00M | $3.36M | $0 | $29.09M | $18.48M | $26.71M |
| Stock-based compensation | $654.0K | $671.0K | $552.0K | $475.0K | $416.0K | $350.0K | $340.0K | $2.07M | $3.41M | $4.01M |
| Depreciation and amortization | $108.0K | $137.0K | $135.0K | $85.0K | $87.0K | $201.0K | $240.0K | $272.0K | $245.0K | $157.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -164.1% | -134.5% | -49.6% | -38.0% | -21.8% | - | - | -94.4% | - | -1205.4% |
| Return on assets | -66.0% | -72.6% | -33.2% | -27.4% | -20.3% | -119.4% | -88.8% | -44.3% | -80.5% | -121.1% |
| Current ratio | 1.74 | 2.15 | 4.07 | 6.45 | 19.37 | 2.67 | 3.11 | 8.72 | 1.83 | 1.09 |
| Debt to equity | 0.11 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $300.0K | - | - | - | - | - | - | - | - | - | - |
| Research and development | $1.27M | $355.0K | $1.13M | $2.55M | $1.95M | $2.97M | $2.89M | $2.73M | $2.95M | $3.46M | $4.20M | $4.01M |
| Selling, general and admin | $2.03M | $2.07M | $931.0K | $1.89M | $11.18M | $1.45M | $1.69M | $2.30M | $1.47M | $1.93M | $2.02M | $212.0K |
| Operating income | -$3.29M | -$2.13M | -$2.06M | -$4.44M | -$13.13M | -$4.42M | -$4.58M | -$7.89M | -$8.49M | -$5.39M | -$6.22M | -$4.22M |
| Pre-tax income | -$3.22M | -$2.04M | -$2.00M | -$4.36M | -$13.06M | -$4.32M | -$4.45M | -$7.73M | -$8.32M | -$5.17M | -$5.91M | -$3.83M |
| Income tax | - | - | - | - | - | - | - | - | - | - | -$424.0K | -$527.0K |
| Net income | -$3.22M | -$2.04M | -$3.51M | -$4.36M | -$13.06M | -$4.32M | -$4.45M | -$7.73M | -$8.32M | -$5.17M | -$5.49M | -$3.30M |
| EPS, basic | -$0.07 | -$0.05 | - | -$0.45 | -$1.93 | -$1.55 | - | -$6.81 | -$10.72 | -$7.53 | -$7.63 | -$4.85 |
| EPS, diluted | -$0.07 | -$0.05 | - | -$0.45 | -$1.93 | -$1.55 | - | -$6.81 | -$10.72 | -$7.53 | -$7.63 | -$4.85 |
| Diluted shares | 45.9M | 41.1M | - | 9.7M | 6.8M | 2.8M | - | 1.1M | 775,736 | 685,923 | - | 681,708 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.34M | $14.43M | $13.06M | $7.53M | $12.12M | $10.01M | $11.71M | $16.41M | $16.59M | $18.26M | $23.28M | $31.16M |
| Current assets | $13.67M | $16.76M | $17.47M | $9.90M | $14.74M | $12.48M | $16.28M | $19.53M | $19.71M | $21.66M | $27.40M | $34.77M |
| Goodwill | - | - | - | - | - | - | $0 | - | $1.47M | $5.57M | $5.70M | $5.46M |
| Total assets | $34.86M | $38.25M | $38.24M | $30.84M | $35.83M | $32.16M | $35.35M | $40.11M | $42.39M | $48.73M | $55.22M | $61.55M |
| Current liabilities | $12.11M | $10.26M | $10.01M | $11.00M | $12.39M | $8.15M | $7.58M | $7.32M | $6.85M | $6.01M | $6.74M | $8.74M |
| Short-term debt | - | - | - | - | - | - | - | - | - | - | $63.0K | $65.0K |
| Total debt | - | - | $1.67M | - | - | - | $92.0K | - | - | - | $162.0K | $150.0K |
| Total liabilities | $22.67M | $22.85M | $22.86M | $24.10M | $25.21M | $16.66M | $16.29M | $15.47M | $14.74M | $14.61M | $15.52M | $17.66M |
| Shareholders' equity | $12.19M | $15.40M | $15.38M | $6.74M | $10.62M | $15.50M | $19.07M | $24.64M | $25.90M | $31.39M | $36.96M | $41.15M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.08M | -$2.46M | -$2.88M | -$4.32M | -$4.71M | -$4.76M | -$4.69M | -$3.91M | -$3.45M | -$4.88M | -$6.54M | -$2.95M |
| Capital expenditures | - | - | $0 | $19.0K | - | - | $0 | $0 | - | - | $56.0K | $129.0K |
| Free cash flow | - | - | -$2.88M | -$4.34M | - | - | -$4.69M | -$3.91M | - | - | -$6.60M | -$3.08M |
| Investing cash flow | - | - | $0 | -$19.0K | - | - | $0 | $0 | - | - | -$56.0K | -$129.0K |
| Financing cash flow | -$14.0K | $3.87M | $8.46M | -$148.0K | $6.81M | $3.07M | $7.0K | $3.72M | - | - | -$1.46M | $1.0K |
| Stock-based compensation | $135.0K | $135.0K | $153.0K | $228.0K | $173.0K | $100.0K | $162.0K | $177.0K | $172.0K | $160.0K | $145.0K | $135.0K |
| Depreciation and amortization | $24.0K | $24.0K | $27.0K | $28.0K | $27.0K | $26.0K | $27.0K | $33.0K | $38.0K | $39.0K | $39.0K | $32.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | -709.0% | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | -681.3% | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 1.13 | 1.63 | 1.74 | 0.90 | 1.19 | 1.53 | 2.15 | 2.67 | 2.88 | 3.60 | 4.07 | 3.98 |
| Debt to equity | - | - | 0.11 | - | - | - | 0.00 | - | - | - | 0.00 | 0.00 |
Source: XBRL data Theriva Biologics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-35, first reported Nov 8, 2018; 1-for-10, first reported Nov 10, 2022; 1-for-25, first reported Nov 12, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TOVX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TOVX | - | - | -$13.13M | - | $8.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
TOVX FAQ
4 questionsIs TOVX profitable?
No. Theriva Biologics Inc. reported a net loss of $13.13M for the twelve months ended Jun 30, 2026.How much cash and debt does TOVX have?
Theriva Biologics Inc. reported $11.34M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did TOVX last report financial results?
The latest statements here come from Theriva Biologics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this TOVX financial data come from?
Quantisnow builds these statements from the structured XBRL data Theriva Biologics Inc. files with the SEC. It is provided for information only and is not investment advice.